TAGLN expression is upregulated in NF1-associated malignant peripheral nerve sheath tumors by hypomethylation in its promoter and subpromoter regions

Park,Gun-Hoo; Lee,Su-Jin; Yim,Hyunee; Han,Jae-Ho; Kim,Hyon  J.; Sohn,Young-Bae; Ko,Jung  Min; Jeong,Seon-Yong

doi:10.3892/or.2014.3379

TAGLN expression is upregulated in NF1-associated malignant peripheral nerve sheath tumors by hypomethylation in its promoter and subpromoter regions

Authors:
- Gun-Hoo Park
- Su-Jin Lee
- Hyunee Yim
- Jae-Ho Han
- Hyon J. Kim
- Young-Bae Sohn
- Jung Min Ko
- Seon-Yong Jeong
View Affiliations

Affiliations: Department of Medical Genetics, Ajou University School of Medicine, Suwon, Republic of Korea, Department of Pathology, Ajou University School of Medicine, Suwon, Republic of Korea, Department of Pediatrics, Seoul National University Children's Hospital, Seoul, Republic of Korea
Published online on: August 4, 2014 https://doi.org/10.3892/or.2014.3379
Pages: 1347-1354
Copyright: © Park et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neurofibromatosis type 1 (NF1) caused by NF1 gene mutation is a commonly inherited autosomal dominant disorder. Malignant peripheral nerve sheath tumors (MPNSTs), a type of aggressive sarcoma, are a major cause of mortality in NF1 patients. The malignant transformation of benign plexiform neurofibromas (PNs) to MPNSTs is a marked peculiarity in NF1 patients, yet the pathogenesis remains poorly understood. We found that an actin-associated protein transgelin (SM22) was highly expressed in NF1-deficient MPNST tissues compared to NF1-deficient PN tissues using immunohistological staining and primary cultured MPNST cells in western blot analysis. We further found that this transgelin upregulation was caused by increased transcriptional expression of the TAGLN gene encoding transgelin. Comparison of DNA methylation values in the promoter and subpromoter regions of the TAGLN gene in three types of NF1-deficient primary-cultured cells, derived from an NF1 patient's normal phenotype, a benign PN and MPNST tissues, revealed that the TAGLN gene was hypomethylated in the MPNST cells. Next, to determine the functional role of transgelin in MPNST pathogenesis, we manipulated the TAGLN gene expression and investigated the alteration of the RAS-mitogen-activated protein kinase (MAPK) signaling pathway in the normal-phenotypic and malignant tumor cells. The downregulation of TAGLN expression in NF1-deficient MPNST tumor cells through the treatment of the small interfering RNA resulted in a decrease in the RAS activation (GTP-RAS) and the downstream ERK1/2 activation (phosphorylated ERK1/2), while the overexpression of TAGLN in normal-phenotypic NF1-deficient cells caused an increase in RAS and ERK1/2 activation. These results indicate that upregulation of transgelin caused by hypomethylation of the TAGLN gene is closely involved in tumor progression in NF1.

View Figures

View References

1	Boyd KP, Korf BR and Theos A: Neurofibromatosis type 1. J Am Acad Dermatol. 61:1–14. 2009. View Article : Google Scholar
2	McClatchey AI: Neurofibromatosis. Annu Rev Pathol. 2:191–216. 2007. View Article : Google Scholar
3	Cawthon RM, Weiss R, Xu GF, et al: A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell. 62:193–201. 1990. View Article : Google Scholar : PubMed/NCBI
4	Jett K and Friedman JM: Clinical and genetic aspects of neurofibromatosis 1. Genet Med. 12:1–11. 2010. View Article : Google Scholar
5	Katz D, Lazar A and Lev D: Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways. Expert Rev Mol Med. 11:e302009. View Article : Google Scholar : PubMed/NCBI
6	Evans DG, Baser ME, McGaughran J, Sharif S, Howard E and Moran A: Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 39:311–314. 2002. View Article : Google Scholar : PubMed/NCBI
7	Grobmyer SR, Reith JD, Shahlaee A, Bush CH and Hochwald SN: Malignant peripheral nerve sheath tumor: molecular pathogenesis and current management considerations. J Surg Oncol. 97:340–349. 2008. View Article : Google Scholar : PubMed/NCBI
8	Brems H, Beert E, de Ravel T and Legius E: Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol. 10:508–515. 2009. View Article : Google Scholar : PubMed/NCBI
9	Thway K and Fisher C: Malignant peripheral nerve sheath tumor: pathology and genetics. Ann Diagn Pathol. 18:109–116. 2014. View Article : Google Scholar : PubMed/NCBI
10	U padhyaya M, Kluwe L, Spurlock G, et al: Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs). Hum Mutat. 29:74–82. 2008.
11	Kluwe L, Friedrich RE and Mautner VF: Allelic loss of the NF1 gene in NF1-associated plexiform neurofibromas. Cancer Genet Cytogenet. 113:65–69. 1999.
12	Legius E, Dierick H, Wu R, et al: TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosomes Cancer. 10:250–255. 1994. View Article : Google Scholar : PubMed/NCBI
13	Nielsen GP, Stemmer-Rachamimov AO, Ino Y, Moller MB, Rosenberg AE and Louis DN: Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol. 155:1879–1884. 1999. View Article : Google Scholar : PubMed/NCBI
14	Mawrin C, Kirches E, Boltze C, Dietzmann K, Roessner A and Schneider-Stock R: Immunohistochemical and molecular analysis of p53, RB, and PTEN in malignant peripheral nerve sheath tumors. Virchows Arch. 440:610–615. 2002. View Article : Google Scholar : PubMed/NCBI
15	Upadhyaya M: Genetic basis of tumorigenesis in NF1 malignant peripheral nerve sheath tumors. Front Biosci. 16:937–951. 2011. View Article : Google Scholar : PubMed/NCBI
16	Mo W, Chen J, Patel A, et al: CXCR4/CXCL12 mediate autocrine cell-cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell. 152:1077–1090. 2013. View Article : Google Scholar : PubMed/NCBI
17	Lévy P, Ripoche H, Laurendeau I, et al: Microarray-based identification of tenascin C and tenascin XB, genes possibly involved in tumorigenesis associated with neurofibromatosis type 1. Clin Cancer Res. 13:398–407. 2007.
18	Watanabe T, Oda Y, Tamiya S, Masuda K and Tsuneyoshi M: Malignant peripheral nerve sheath tumour arising within neurofibroma. An immunohistochemical analysis in the comparison between benign and malignant components. J Clin Pathol. 54:631–636. 2001. View Article : Google Scholar
19	Johannessen CM, Reczek EE, James MF, Brems H, Legius E and Cichowski K: The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA. 102:8573–8578. 2005. View Article : Google Scholar : PubMed/NCBI
20	Park HJ, Lee SJ, Sohn YB, et al: NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Int J Oncol. 42:657–666. 2013.
21	Carroll SL and Ratner N: How does the Schwann cell lineage form tumors in NF1? Glia. 56:1590–1605. 2008. View Article : Google Scholar : PubMed/NCBI
22	Gregorian C, Nakashima J, Dry SM, et al: PTEN dosage is essential for neurofibroma development and malignant transformation. Proc Natl Acad Sci USA. 106:19479–19484. 2009. View Article : Google Scholar : PubMed/NCBI
23	Yu J, Deshmukh H, Payton JE, et al: Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor. Clin Cancer Res. 17:1924–1934. 2011.PubMed/NCBI
24	Stricker TP, Henriksen KJ, Tonsgard JH, Montag AG, Krausz TN and Pytel P: Expression profiling of 519 kinase genes in matched malignant peripheral nerve sheath tumor/plexiform neurofibroma samples is discriminatory and identifies mitotic regulators BUB1B, PBK and NEK2 as overexpressed with transformation. Mod Pathol. 26:930–943. 2013. View Article : Google Scholar
25	Kulis M and Esteller M: DNA methylation and cancer. Adv Genet. 70:27–56. 2010. View Article : Google Scholar
26	Malumbres M: miRNAs and cancer: an epigenetics view. Mol Aspects Med. 34:863–874. 2013. View Article : Google Scholar : PubMed/NCBI
27	Sedani A, Cooper DN and Upadhyaya M: An emerging role for microRNAs in NF1 tumorigenesis. Hum Genomics. 6:232012. View Article : Google Scholar : PubMed/NCBI
28	Subramanian S, Thayanithy V, West RB, et al: Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J Pathol. 220:58–70. 2010. View Article : Google Scholar : PubMed/NCBI
29	Masliah-Planchon J, Pasmant E, Luscan A, et al: MicroRNAome profiling in benign and malignant neurofibromatosis type 1-associated nerve sheath tumors: evidences of PTEN pathway alterations in early NF1 tumorigenesis. BMC Genomics. 14:4732013. View Article : Google Scholar
30	Itani S, Kunisada T, Morimoto Y, et al: MicroRNA-21 correlates with tumorigenesis in malignant peripheral nerve sheath tumor (MPNST) via programmed cell death protein 4 (PDCD4). J Cancer Res Clin Oncol. 138:1501–1509. 2012. View Article : Google Scholar : PubMed/NCBI
31	Ferner RE, Huson SM, Thomas N, et al: Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet. 44:81–88. 2007. View Article : Google Scholar
32	Lee SJ, Park HJ, Kim YH, et al: Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells. Int J Mol Med. 30:443–450. 2012.PubMed/NCBI
33	Bibikova M and Fan JB: Genome-wide DNA methylation profiling. Wiley Interdiscip Rev Syst Biol Med. 2:210–223. 2010. View Article : Google Scholar
34	Jeong SY, Han JH, Park YY and Kim HJ: Identification of differentially expressed genes related to NF1-associated malignant transformation from a patient with neurofibromatosis type 1. Genes Genomics. 30:407–418. 2008.
35	Hirasawa Y, Arai M, Imazeki F, et al: Methylation status of genes upregulated by demethylating agent 5-aza-2′-deoxycytidine in hepatocellular carcinoma. Oncology. 71:77–85. 2006.
36	Zhao L, Wang H, Deng YJ, et al: Transgelin as a suppressor is associated with poor prognosis in colorectal carcinoma patients. Mod Pathol. 22:786–796. 2009.PubMed/NCBI
37	Stanier P, Abu-Hayyeh S, Murdoch JN, Eddleston J and Copp AJ: Paralogous sm22α (Tagln) genes map to mouse chromosomes 1 and 9: further evidence for a paralogous relationship. Genomics. 51:144–147. 1998.
38	Li Y, Rao PK, Wen R, et al: Notch and Schwann cell transformation. Oncogene. 23:1146–1152. 2004. View Article : Google Scholar : PubMed/NCBI
39	Grønbaek K, Hother C and Jones PA: Epigenetic changes in cancer. APMIS. 115:1039–1059. 2007.
40	Ehrlich M and Lacey M: DNA hypomethylation and hemimethylation in cancer. Adv Exp Med Biol. 754:31–56. 2013. View Article : Google Scholar : PubMed/NCBI
41	Suzuki H, Maruyama R, Yamamoto E and Kai M: DNA methylation and microRNA dysregulation in cancer. Mol Oncol. 6:567–578. 2012. View Article : Google Scholar
42	Harder A, Titze S, Herbst L, et al: Monozygotic twins with neurofibromatosis type 1 (NF1) display differences in methylation of NF1 gene promoter elements, 5′ untranslated region, exon and intron 1. Twin Res Hum Genet. 13:582–594. 2010.PubMed/NCBI
43	Titze S, Peters H, Währisch S, et al: Differential MSH2 promoter methylation in blood cells of Neurofibromatosis type 1 (NF1) patients. Eur J Hum Genet. 18:81–87. 2010.
44	Fishbein L, Eady B, Sanek N, Muir D and Wallace MR: Analysis of somatic NF1 promoter methylation in plexiform neurofibromas and Schwann cells. Cancer Genet Cytogenet. 157:181–186. 2005.PubMed/NCBI
45	Harder A, Rosche M, Reuss DE, et al: Methylation analysis of the neurofibromatosis type 1 (NF1) promoter in peripheral nerve sheath tumours. Eur J Cancer. 40:2820–2828. 2004. View Article : Google Scholar : PubMed/NCBI
46	Bradtmöller M, Hartmann C, Zietsch J, et al: Impaired Pten expression in human malignant peripheral nerve sheath tumours. PLoS One. 7:e475952012.PubMed/NCBI
47	Camoretti-Mercado B, Forsythe SM, LeBeau MM, et al: Expression and cytogenetic localization of the human SM22 gene (TAGLN). Genomics. 49:452–457. 1998. View Article : Google Scholar : PubMed/NCBI
48	Yamamura H, Masuda H, Ikeda W, et al: Structure and expression of the human SM22α gene, assignment of the gene to chromosome 11, and repression of the promoter activity by cytosine DNA methylation. J Biochem. 122:157–167. 1997.
49	Assinder SJ, Stanton JA and Prasad PD: Transgelin: an actin-binding protein and tumour suppressor. Int J Biochem Cell Biol. 41:482–486. 2009. View Article : Google Scholar : PubMed/NCBI
50	Dvorakova M, Nenutil R and Bouchal P: Transgelins, cytoskeletal proteins implicated in different aspects of cancer development. Expert Rev Proteomics. 11:149–165. 2014. View Article : Google Scholar : PubMed/NCBI
51	Dos Santos Hidalgo G, Meola J, Rosa E, Silva JC, Paro de Paz CC and Ferriani RA: TAGLN expression is deregulated in endometriosis and may be involved in cell invasion, migration, and differentiation. Fertil Steril. 96:700–703. 2011.PubMed/NCBI
52	Zhou L, Zhang R, Zhang L, et al: Upregulation of transgelin is an independent factor predictive of poor prognosis in patients with advanced pancreatic cancer. Cancer Sci. 104:423–430. 2013. View Article : Google Scholar : PubMed/NCBI
53	Yu B, Chen X, Li J, et al: Stromal fibroblasts in the microenvironment of gastric carcinomas promote tumor metastasis via upregulating TAGLN expression. BMC Cell Biol. 14:172013. View Article : Google Scholar : PubMed/NCBI
54	Gottfried ON, Viskochil DH, Fults DW and Couldwell WT: Molecular, genetic, and cellular pathogenesis of neurofibromas and surgical implications. Neurosurgery. 58:1–16. 2006. View Article : Google Scholar : PubMed/NCBI
55	Carroll SL: Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms. Acta Neuropathol. 123:321–348. 2012. View Article : Google Scholar : PubMed/NCBI
56	Kalluri R and Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer. 6:392–401. 2006. View Article : Google Scholar
57	Shields JM, Rogers-Graham K and Der CJ: Loss of transgelin in breast and colon tumors and in RIE-1 cells by Ras deregulation of gene expression through Raf-independent pathways. J Biol Chem. 277:9790–9799. 2002. View Article : Google Scholar : PubMed/NCBI
58	Adammek M, Greve B, Kässens N, et al: MicroRNA miR-145 inhibits proliferation, invasiveness, and stem cell phenotype of an in vitro endometriosis model by targeting multiple cytoskeletal elements and pluripotency factors. Fertil Steril. 99:1346–1355.e5. 2013. View Article : Google Scholar
59	Vairaktaris E, Kalokerinos G, Goutzanis L, et al: Diabetes enhances cell proliferation but not Bax/Bcl-2-mediated apoptosis during oral oncogenesis. Int J Oral Maxillofac Surg. 37:60–65. 2008. View Article : Google Scholar : PubMed/NCBI
60	Sinčić N and Herceg Z: DNA methylation and cancer: ghosts and angels above the genes. Curr Opin Oncol. 23:69–76. 2011.PubMed/NCBI